Neurology
Page 1 • 12 itemsGain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+
Travere Therapeutics receives FDA approval for FILSPARI to reduce proteinuria in FSGS patients aged 8 and older, expanding rare kidney disease treatment options.
Keenova Therapeutics Presents New TERLIVAZ Clinical Data for Hepatorenal Syndrome at Digestive Disease Week 2026
Keenova Therapeutics shares new TERLIVAZ (terlipressin) clinical analysis for hepatorenal syndrome-acute kidney injury at DDW 2026, expanding treatment evidence.
Axoft Raises $55M Series A to Advance Brain-Computer Interface Clinical Trials Globally
Axoft secures $55M Series A funding led by C.P. Group Innovation to advance bio-inspired brain-computer interface technology into global clinical trials.
Newleos Begins Phase 1b Trial of NTX-2001 for Alcohol Use Disorder Treatment
Newleos doses first patient in Phase 1b study of NTX-2001, a TAAR1 partial agonist targeting alcohol use disorder, marking key development milestone.
Claruvis Pharmaceutical's Retoxin Becomes World's First Approved Recombinant Botulinum Toxin Type A in China
China's NMPA approves Retoxin, the world's first recombinant botulinum toxin type A, marking a technological breakthrough in aesthetic medicine treatments.
Arcera Life Sciences Partners with Fosun Pharma for Neurodegenerative Disease R&D Collaboration
Arcera Life Sciences and Fosun Pharma establish strategic framework for neurodegenerative disease research, licensing, and technology development.
Immunic Appoints Dr. Michael Panzara as Chief Medical Officer to Lead Vidofludimus Calcium Development
Immunic Inc. names multiple sclerosis drug development expert Dr. Michael Panzara as CMO to advance Vidofludimus Calcium through pivotal trials.
Daewoong Pharmaceutical NABOTA Master Class Highlights PrabotulinumtoxinA Safety for High-Dose Treatments
Daewoong Pharmaceutical hosted 74 healthcare professionals from 13 countries for NABOTA Master Class, emphasizing PrabotulinumtoxinA safety protocols.
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Spinogenix initiates CLARITY Phase 2b/3 trial testing SPG601, a first-in-class oral therapy targeting BK channels for Fragile X Syndrome in male patients.
SynSmart and Amporin Partner to Develop Small Molecule Therapeutics for Degenerative Diseases
SynSmart Rasayan Research and Amporin Pharmaceuticals announce collaboration to develop breakthrough small molecule treatments for fatal degenerative diseases.
Methylphenidate Shortage Update: Concerta and Ritalin LA Supply Restored, Rubifen LA Expected by June 2026
Australia's methylphenidate shortage shows improvement as Concerta and Ritalin LA supplies normalize, while Rubifen LA shortages persist until mid-2026.
P&G Health Launches First APAC Pharmacist Guidelines for Peripheral Neuropathy Management
P&G Health and APAC experts release region's first community pharmacist guidelines for peripheral neuropathy, affecting 1 in 2 diabetics and 1 in 10 adults.